H.C. Wainwright analyst Andres Y. Maldonado has reiterated their bullish stance on ENGN stock, giving a Buy rating on February 25.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Andres Y. Maldonado has given his Buy rating due to a combination of factors related to enGene’s lead asset, detalimogene, and its strategic fit in the non–muscle invasive bladder cancer market. He highlights that the LEGEND pivotal cohort has completed enrollment at a meaningful scale, with response rates that are competitive and sustained over time, while maintaining a favorable safety and tolerability profile that suits high-risk BCG-unresponsive patients.
Maldonado also underscores that detalimogene’s off-the-shelf, BCG-like administration, straightforward storage, and buy-and-bill compatibility make it highly attractive for community urology practices that dominate this treatment setting. Coupled with clear regulatory momentum, inclusion in the FDA’s CMC pilot program, and funding that extends beyond the planned BLA submission, he views enGene as well positioned to gain real-world market share and therefore reiterates a Buy rating and $25 price target.
In another report released on February 25, Jefferies also maintained a Buy rating on the stock with a $28.00 price target.